BioPharm International-09-01-2004

BioPharm International

Editorial—Public Pressure, the Press, Politics, and Profits

September 01, 2004

Columns and Departments

17

9

American patients are more educated about health issues than any prior generation, thanks to the Internet. I read somewhere that doctors, from family physicians to specialists, are amazed at how well prepared their patients are when they show up for an appointment — with documentation in tow after researching conditions, medications, and treatments. So much so that the doctors are stressed out from trying to answer all their questions, complete their exams, and get everyone out the door in the amount of time the insurance companies say is "reasonable."

French Biotech: A Fast-Growing Industry

September 01, 2004

International BioMarket

17

9

Over the last 20 years, France has become a major hub of the European biotechnology sector. The renewed French interest emerged from the perception that progress in biotechnology is good not only for the country's economy but also for the well being of people worldwide and both the private and the public sectors.

Optimization, scale-up, and validation ISSUES in FILTRATION of Biopharmaceuticals, Part II

September 01, 2004

Filtration

17

9

Filtration is one of the most commonly used unit operations in the manufacturing of biopharmaceuticals. This is the second part of the fourth article in the "Elements of Biopharmaceutical Production" series. In this second segment, Manoj Menon and Frank Riske present an approach for the development and optimization of a TFF application, followed by a contribution from Jennifer Campbell and Elizabeth Goodrich reviewing key issues involved in validation of a TFF step.

Overseas Outsourcing: The Advantages of IT Offshoring

September 01, 2004

Outsourcing

17

9

Life sciences firms haven't exactly been jumping on the offshore outsourcing bandwagon. But faced with unprecedented cost constraints, competitive pressures, and regulatory scrutiny, the industry needs new solutions to its business problems. Some experts think information technology (IT) "offshoring" offers a solid alternative; others question the idea.

Final Word: World Firsts — From the Double Helix to Therapeutic Cloning

September 01, 2004

Columns and Departments

17

9

The US will, beyond doubt, remain the world leader in life sciences for the foreseeable future. However, as with other sectors, bioscience - both R&D and business - is increasingly global. For US researchers and business leaders alike, it makes increasing sense to look beyond the shores of America for both expertise and profit-making opportunities. For many, the principal partner of choice has been - and will remain - the United Kingdom. There are sound reasons for this.